Bone Marrow Transplant Rejection – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23005IDB-L5

Select Item

Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions.

Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient’s body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs.

The Bone Marrow Transplant Rejection drugs in development market research report provide comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Bone Marrow Transplant Rejection
Key Targets
· Tyrosine Protein Kinase JAK1; Tyrosine Protein Kinase JAK2; Macrophage Colony Stimulating Factor 1 Receptor; Interleukin 2 Receptor Subunit Beta; Programmed Cell Death Protein 1; Tyrosine Protein Kinase BTK; Alpha 1 Antitrypsin; B And T Lymphocyte Attenuator; Interleukin 2 Receptor; and T Cell Differentiation Antigen CD6
Key Mechanisms of Action
· Tyrosine Protein Kinase JAK1 Inhibitor; Tyrosine Protein Kinase JAK2 Inhibitor; Tyrosine Protein Kinase BTK Inhibitor; Alpha 1 Antitrypsin Replacement; Macrophage Colony Stimulating Factor 1 Receptor Inhibitor; Interleukin 2 Receptor Subunit Beta Antagonist; Interleukin 2 Receptor Agonist; B And T Lymphocyte Attenuator Agonist; Tyrosine Protein Kinase ITK/TSK Inhibitor; and Rho Associated Protein Kinase 2 Inhibitor
Key Routes of Administration
· Intravenous; Oral; Subcutaneous; Parenteral; Topical; Intramuscular; Intravenous Drip; Intraperitoneal; Intraarticular; and Intracoronary
Key Molecule Types
· Small Molecule; Cell Therapy; Monoclonal Antibody; Gene-Modified Cell Therapy; Recombinant Protein; Fusion Protein; Biologic; Antibody; Synthetic Peptide; and Blood Derivative
Major Companies
· Shenzhen Chipscreen Biosciences Co Ltd; Pfizer Inc; Incyte Corp; H. Lee Moffitt Cancer Center & Research Institute Inc; Bristol-Myers Squibb Co; AnaptysBio Inc; AstraZeneca Plc; Cellvation Inc; CheckPoint Immunology Inc; and EV Therapeutics Inc

Scope

  • Therapeutics in Development: Covering 201 molecules, with 181 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Bone Marrow Transplant Rejection therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Bone Marrow Transplant Rejection pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bone Marrow Transplant Rejection treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

9 Meters Biopharma Inc
Abbisko Therapeutics Co Ltd
AbbVie Inc
AbolerIS Pharma
Accro Bioscience Suzhou Co Ltd
Actitrexx GmbH
Adienne Pharma & Biotech SA
Aegle Therapeutics Corp
AffyXell Therapeutics Co Ltd
Alphamab Oncology
AltruBio Inc
AnaMar AB
AnaptysBio Inc
ARScience Biotherapeutics Inc
ASC Therapeutics Inc
AstraZeneca Plc
Athos Therapeutics Inc
Avalon GloboCare Corp
Azura Ophthalmics Pty Ltd
Baudax Bio Inc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
Biotech Pharmaceutical Co Ltd
Biotest AG
BK Pharmaceuticals Ltd
BlueRock Therapeutics LLC
BlueSphere Bio Inc
Boryung ViGenCell Inc
Boston Immune Technologies and Therapeutics Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cell Source Inc
Cellective BioTherapy Inc
Cellenkos Inc
Cellestia Biotech AG
Celloram Inc
Celltrion Inc
Cellvation Inc
CheckPoint Immunology Inc
Cincinnati Children's Hospital Medical Center
City of Hope
Compugen Ltd
Corvus Pharmaceuticals Inc
Createrna Science and Technology Co Ltd
Crestone Inc
CSL Ltd
CTI BioPharma Corp
Cue Biopharma Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dmitry Rogachev National Research Center of Pediatric Hematology
Oncology and Immunology
Dualogics Corp
Dualyx NV
Dystrogen Therapeutics SA
Educell doo
Eli Lilly and Co
Emory University
enGene Holdings Inc
Equillium Inc
EV Therapeutics Inc
Evive Biotech
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Forte Biosciences Inc
Fraunhofer Institute for Cell Therapy and Immunology
French National Institute of Health and Medical Research
Fujifilm Holdings Corp
Genentech USA Inc
General Nanotherapeutics LLC
GigaGen Inc
Glia LLC
Good T Cells Inc
Gracell Biotechnologies Inc
GSK plc
Guangdong ProCapZoom Biosciences Co Ltd
H. Lee Moffitt Cancer Center & Research Institute Inc
Hangzhou East China Pharmaceutical Group Co Ltd
HiFiBiO Therapeutics Inc
Humanigen Inc
iCELL Biotechnology Co Ltd
Immune Modulation Inc
ImmuneMed Inc
ImmunoBiome Inc
Imstem Biotechnology Inc
Incyte Corp
Indiana University
Inhibrx Inc
iNtRON Biotechnology Inc
Iovance Biotherapeutics Inc
Ironwood Pharmaceuticals Inc
ITB-Med AB
Jiangsu Hengrui Medicine Co Ltd
JN Biosciences LLC
Kadmon Holdings Inc
Kamada Pharmaceuticals
Kiji Therapeutics
Kymab Ltd
Lipella Pharmaceuticals Inc
Lysatpharma GmbH
MaaT Pharma
Machavert Pharmaceuticals LLC
Medexus Pharmaceuticals Inc
Mediolanum farmaceutici SpA
Medsenic SAS
Merck & Co Inc
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
MiNK Therapeutics Inc
MitoImmune Therapeutics Inc
Moderna Inc
Monash University
NapaJen Pharma Inc
Neoleukin Therapeutics Inc
Neovii Pharmaceuticals AG
NeuImmune Inc
Novartis AG
NXI Therapeutics AG
Orca Biosystems Inc
Oregon State University
Ossium Health Inc
Panorama Research Institute
Parenchyma Biotech
PB Immune Therapeutics Co Ltd
Pfizer Inc
Platinum Biotech (Beijing) Co Ltd
Plexxikon Inc
Pluri Inc
Precision Biosciences Inc
ProGen Co Ltd
ReAlta Life Sciences Inc
Rebus Holdings Inc
Redx Pharma Plc
REGiMMUNE Corp
RHEACELL GmbH & Co KG
Rheos Medicines Inc
Romeck Pharma LLC
San Raffaele Scientific Institute
Sanofi
SCM lifescience Co Ltd
Seagen Inc
Seres Therapeutics Inc
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sidney Kimmel Comprehensive Cancer Center
Sino Biopharmaceutical Ltd
STERO Biotechs Ltd
StingInn LLC
SUNY Upstate Medical University
Suzhou Connect Biopharmaceuticals Ltd
Suzhou Regend Therapeutics Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Syndax Pharmaceuticals Inc
Takeda Pharmaceutical Co Ltd
Tcell Tolerance GmbH
TCF GmbH
Theriva Biologics Inc
Tianjin Angsai Cell Genetic Engineering Co Ltd
Tianjin Madison Regenerative Medicine Co Ltd
Trailhead Biosystems Inc
TreeFrog Therapeutics SAS
Triursus Therapeutics Inc
United BioPharma Inc
University of Patras
University of Southern California
Vault Pharma Inc
Vectans Pharma SAS
Veloxis Pharmaceuticals Inc
Viracta Therapeutics Inc
VITRAC Therapeutics LLC
Wake Forest University
Washington University in St Louis
Wistar Institute
Xbiome Co Ltd
Xenothera SAS
Xlock Biosciences LLC
Zephyrm Biotechnologies Co Ltd
Zr Pharma & Gmbh

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Bone Marrow Transplant Rejection reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bone Marrow Transplant Rejection – Drugs In Development, 2024 in real time.

  • Access a live Bone Marrow Transplant Rejection – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more